About Corcept Therapeutics (NASDAQ:CORT)
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CORT
CUSIP21835210
Phone650-688-8803
Debt
Debt-to-Equity RatioN/A
Current Ratio5.44
Quick Ratio5.26
Price-To-Earnings
Trailing P/E Ratio38.36
Forward P/E Ratio23.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$159.20 million
Price / Sales12.22
Cash Flow$0.4010 per share
Price / Cash42.10
Book Value$1.67 per share
Price / Book10.11
Profitability
EPS (Most Recent Fiscal Year)$0.44
Net Income$129.12 million
Net Margins75.05%
Return on Equity46.78%
Return on Assets39.56%
Miscellaneous
Employees136
Outstanding Shares115,240,000
Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions
What is Corcept Therapeutics' stock symbol?
Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics' earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported $0.19 EPS for the quarter, topping the Zacks' consensus estimate of $0.18 by $0.01. The biotechnology company earned $57.66 million during the quarter, compared to the consensus estimate of $58.18 million. Corcept Therapeutics had a return on equity of 46.78% and a net margin of 75.05%. The company's revenue for the quarter was up 108.9% compared to the same quarter last year. During the same period last year, the firm earned $0.06 earnings per share. View Corcept Therapeutics' Earnings History.
When is Corcept Therapeutics' next earnings date?
What price target have analysts set for CORT?
5 brokerages have issued 12 month price objectives for Corcept Therapeutics' shares. Their predictions range from $20.00 to $32.00. On average, they expect Corcept Therapeutics' share price to reach $26.40 in the next twelve months. View Analyst Ratings for Corcept Therapeutics.
Who are some of Corcept Therapeutics' key competitors?
Some companies that are related to Corcept Therapeutics include Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM) and Madrigal Pharmaceuticals (MDGL).
Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the folowing people:
- Dr. Joseph K. Belanoff M.D., Co-Founder, CEO, Pres & Director (Age 61)
- Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 55)
- Dr. Robert S. Fishman M.D., ? F.C.C.P., Chief Medical Officer (Age 56)
- Dr. Hazel Hunt Ph.D., Sr. VP of Research
- Donald E. Laferle, Sr. VP
Has Corcept Therapeutics been receiving favorable news coverage?
News headlines about CORT stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corcept Therapeutics earned a news impact score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.69 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Corcept Therapeutics' major shareholders?
Corcept Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.20%), Federated Investors Inc. PA (11.01%), Dimensional Fund Advisors LP (1.37%), Northern Trust Corp (0.97%), Nexthera Capital LP (0.91%) and Russell Investments Group Ltd. (0.68%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.
Which major investors are selling Corcept Therapeutics stock?
CORT stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Old Mutual Global Investors UK Ltd., Mckinley Capital Management LLC Delaware, PNC Financial Services Group Inc., Oak Ridge Investments LLC, Smith Asset Management Group LP, ClariVest Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Corcept Therapeutics company stock in the last year include David L Mahoney, G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.
Which major investors are buying Corcept Therapeutics stock?
CORT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Timpani Capital Management LLC, ETRADE Capital Management LLC, State of Tennessee Treasury Department and Federated Investors Inc. PA. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.
How do I buy shares of Corcept Therapeutics?
Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics' stock price today?
One share of CORT stock can currently be purchased for approximately $16.88.
How big of a company is Corcept Therapeutics?
Corcept Therapeutics has a market capitalization of $2.23 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.
How can I contact Corcept Therapeutics?
Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-688-8803 or via email at [email protected]
MarketBeat Community Rating for Corcept Therapeutics (CORT)
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
